S

Solventum

Global healthcare company: wound care, dental

IT Finance and Planning Lead

Full-TimePosted on 10/22/2026
No salary listed
Expert
Bachelor's, MBA
Bengaluru, Karnataka, India
HybridHybrid work in Bangalore.
Finance & BankingCorporate Finance & FP&A

About the job

Requirements
  • A bachelor's degree in Finance, Accounting, Economics, Business Administration, Information Systems, or a related discipline, and 8 or more years of experience in financial planning and analysis, budgeting, forecasting, portfolio financial management, or related finance roles supporting complex technology or business organizations.
  • Recognized expertise in IT or technology finance, including annual planning, forecasting, financial modeling, scenario analysis, variance analysis, investment evaluation, and capital versus operating expense management.
  • Demonstrated results leading complex financial planning cycles or cross-functional financial initiatives, including multiple or integrated plans across IT portfolios, transformation programs, or enterprise investments.
  • Experience advising senior leaders on investment and funding decisions, with recommendations that changed prioritization, spend, or resource allocation.
  • Advanced proficiency in Excel, ERP platforms such as SAP, Oracle, or Workday, or equivalent, and financial planning and reporting tools; ability to turn complex financial data into executive-ready insight.
  • Influence, negotiation, and communication skills to handle differing interests across Finance, IT, Procurement, and business leadership and drive action without direct authority.
Responsibilities
  • Lead IT annual operating plan, budget, forecast, and long-range planning cycles by coordinating inputs across IT functions, challenging assumptions, and contributing to departmental budget decisions aligned with strategic roadmaps and investment priorities.
  • Serve as the subject matter expert for IT financial management, advising IT leadership on investment trade-offs, business cases, total cost of ownership, return on investment, funding alternatives, and capital versus operating expense treatment for technology initiatives and transformation programs.
  • Analyze spending trends, cost drivers, variances, and forecast risks across the IT portfolio; evaluate options and recommend corrective actions and optimization opportunities affecting financial resource allocation across multiple IT teams.
  • Lead cross-functional financial initiatives involving benefits realization, vendor and contract financials, accruals, consumption analysis, and portfolio financial governance, coordinating with Finance, Procurement, and program leaders to deliver on time and within approved budgets.
  • Advise IT leaders with executive-ready financial insight, including scenario analyses, monthly performance reviews, and decision-support materials for prioritization and resource allocation; raise issues with management and stakeholders and secure decisions.
  • Improve planning processes, controls, reporting, and automation, and coach program and project managers across multiple teams on financial planning, forecasting discipline, and compliance with corporate financial policy and audit requirements.
Desired Qualifications
  • MBA, Certified Public Accountant (CPA), Certified Management Accountant (CMA), Chartered Financial Analyst (CFA), or similar professional qualification.
  • Experience with Power BI, Tableau, Alteryx, Anaplan, Adaptive Planning, or similar analytics and planning tools.
  • Knowledge of IT portfolio management, project accounting, resource planning, and benefits realization frameworks.
  • Experience supporting large-scale ERP, cloud, infrastructure, cybersecurity, or digital transformation programs from a financial perspective.
  • Understanding of software licensing economics, vendor financial governance, and contract financial management.
  • Experience coaching or mentoring finance or program colleagues across multiple teams in a global, matrixed organization.

About the company

Solventum provides a wide range of healthcare products across four main areas: wound care and surgical supplies, dental and orthodontic tools, health information software, and purification filters for biopharmaceuticals. These products work by combining material science and data science to help hospitals manage patient records, prevent infections during surgery, and filter fluids for medical treatments like dialysis. Unlike many competitors, the company holds a massive portfolio of over 7,300 patents inherited from its history as a 3M division, allowing it to serve over 75% of U.S. hospitals. Its goal is to use this intellectual property and a disciplined business model to find new solutions for healthcare providers and grow within the global medical technology market.

Company Size

10,001+

Company Stage

IPO

Headquarters

Eagan, Minnesota

Founded

2023

Get referred to Solventum

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 organic sales rose 9.5%, and management raised EPS guidance to $7.10-$7.20.
  • Solventum announced HIS separation on August 5, 2026, sharpening its MedTech focus.
  • The $200 million Eagan Innovation Hub supports roughly 20 launches over two years.

What critics are saying

  • Management expects HIS separation to cut margins about 400 basis points after offsets.
  • ERP cutover orders distorted Q2 2026; Q3 growth resets when demand normalizes.
  • Legal costs, restructuring, and separation complexity keep Solventum exposed until 2027-2028 transactions close.

What makes Solventum unique

  • Solventum combines MedSurg, Dental, and clinical workflow assets from 3M’s healthcare spinout.
  • Its 2026 Eagan Innovation Hub concentrates wound care, sterilization, and digital health R&D.
  • The company still sells into over 75% of U.S. hospitals through entrenched workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

6%

1 year growth

5%

2 year growth

9%
PR Newswire
Oct 19th, 2026
Solventum wins FDA clearance to combine Restrata Matrix with V.A.C. Therapy for wound healing

Solventum has received US Food and Drug Administration (FDA) 510(k) clearance to use Restrata Synthetic Electrospun Fiber Matrix together with its V.A.C. Therapy, the company announced on October 19, 2026. The clearance follows Solventum's acquisition of Acera Surgical in December 2025. Restrata is a fully synthetic, resorbable matrix that supports soft tissue repair, while V.A.C. Therapy applies negative pressure to promote wound healing. Solventum says the matrix resists enzymatic degradation and matches the dressing's wear time of up to seven days. Many collagen-based dressings degrade too early for such use. The pairing may mean fewer dressing changes and a more predictable workflow for care teams. "We're giving clinicians an effective way to streamline care and support better patient outcomes," said Kelley Moffett, president of Advanced Wound Care at Solventum.

Yahoo Finance
Aug 20th, 2026
BrightSpring Health Services posts 23.9% revenue growth as Solventum and Inspire Medical face headwinds

BrightSpring Health Services stands out as a strong long-term healthcare investment, whilst Solventum and Inspire Medical Systems face headwinds, according to recent analysis. Healthcare stocks have surged 27.5% over the past six months, outperforming the S&P 500 by 16.2 percentage points. However, increased venture capital has intensified competition across the sector. BrightSpring, which provides home health care, hospice, and pharmacy services, has achieved 23.9% annual revenue growth over the past two years. Analysts forecast 14.1% revenue growth for the next 12 months. Conversely, Solventum faces weak demand with flat revenue expected, whilst its free cash flow margin has declined 18.2 percentage points over five years. Inspire Medical Systems confronts a forecasted revenue decline of 3.5% for the upcoming year.

Yahoo Finance
Aug 11th, 2026
Solventum beats Q2 estimates with $2.21B revenue, raises EPS guidance 10% amid HIS separation

Healthcare solutions provider Solventum reported second quarter revenue of $2.21 billion, up 2.2% year on year and ahead of analyst estimates of $2.15 billion. Non-GAAP profit of $2.55 per share beat consensus estimates by 33.8%. The company announced plans to separate its Health Information Systems business to focus on its MedSurg and Dental segments. Management said the move would allow the HIS unit to pursue AI-driven innovation whilst sharpening Solventum's focus as a pure-play MedTech company. Second quarter results were temporarily boosted by approximately $125 million in advanced orders placed ahead of a major ERP system transition, which management expects to reverse next quarter. The company raised its full-year adjusted EPS guidance to $7.15 at the midpoint, a 10% increase. Solventum is nearing completion of its separation from 3M.

Yahoo Finance
Aug 9th, 2026
Solventum raises 2026 outlook with 9.5% Q2 growth boosted by $125M advanced orders and $100M tariff refund

Solventum exceeded expectations in Q2, posting $2.2 billion in sales with 9.5% organic growth. However, this included roughly $125 million in advanced ERP-related orders and a $100 million tariff refund. Excluding these benefits, organic growth was approximately 4% and adjusted EPS was estimated at $1.73. The company raised its 2026 outlook, now expecting 2.5%–3% organic sales growth, a 22.2%–22.7% operating margin, adjusted EPS of $7.10–$7.20, and free cash flow of $200 million–$300 million. Third-quarter growth is expected to decline temporarily as the advanced orders reverse. Solventum also announced plans to separate its Health Information Systems business through a potential spin-off or sale, aiming to focus on its MedSurg and Dental segments.

PR Newswire
Aug 5th, 2026
Solventum Q2 sales up 9.5%, raises 2026 guidance and plans to separate Health Information Systems unit

Solventum reported second quarter 2026 sales of $2.2 billion, up 2.2% on a reported basis and 9.5% organically. The MedTech company posted GAAP diluted earnings per share of $0.53 and adjusted diluted EPS of $2.55, marking a 50.9% increase. Operating cash flow reached $227 million, whilst free cash flow totalled $144 million. The strong performance was driven by volume and product mix across all segments, including advance orders ahead of ERP cutovers. Solventum announced plans to separate its Health Information Systems business segment as part of its transformation strategy. The company raised its full-year 2026 guidance, increasing organic sales growth to 2.5% to 3.0%, adjusted EPS to $7.10 to $7.20, and free cash flow to $200 million to $300 million.